Kolchinsky Peter — SEC Form 4 filings
SEC reporting owner CIK 1384859. 158 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers the 50 most recent of 158 filings on record, filed 2026-04-23 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 44 legs across 17 filings — 33,046,427 shares, $578,833,175 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 24 legs across 7 filings — 3,767,503 shares, $67,025,056 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: purchase of 19,728,353 shares @ $20.00 ($394,567,060) in Parabilis Medicines, Inc., filed 2026-06-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | Director, 10% owner | 3 | 8 legs · 21,433,343 sh · $430,694,551 | — | 7 |
| Artiva Biotherapeutics, Inc. (ARTV) | Director, 10% owner | 12 | 20 legs · 8,642,543 sh · $92,678,453 | — | 3 |
| Septerna, Inc. (SEPN) | Director, 10% owner | 2 | — | 2 legs · 1,493,000 sh · $63,452,500 | 1 |
| Hemab Therapeutics Holdings, Inc. (COAG) | 10% owner | 5 | 16 legs · 2,970,541 sh · $55,460,171 | — | 9 |
| Vor Biopharma Inc. (VOR) | 10% owner | 4 | — | 2 legs · 165,363 sh · $2,608,622 | 5 |
| Werewolf Therapeutics, Inc. (HOWL) | 10% owner | 4 | — | 20 legs · 2,109,140 sh · $963,934 | — |
| Freenome, Inc. (FRNM) | Director, 10% owner | 1 | — | — | 7 |
| Acrivon Therapeutics, Inc. (ACRV) | Director, 10% owner | 3 | — | — | 3 |
| Climb Bio, Inc. (CLYM) | Director, 10% owner | 3 | — | — | 3 |
| Acumen Pharmaceuticals, Inc. (ABOS) | Director, 10% owner | 1 | — | — | 2 |
+11 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — Kolchinsky Peter
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M. | Purchase (P): 9,078,529 (derivative) @ $22.03 | EDGAR |
| 2026-09-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 16,250 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2026-08-26 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Option exercise (M): 1,500 @ $3.74 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50 | EDGAR |
| 2026-07-31 | 4 | Inhibikase Therapeutics, Inc. (IKT) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Other (J): 18,030,000 · Other (J): 18,030,000 (derivative) | EDGAR |
| 2026-07-31 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 20,824 @ $9.99 · Purchase (P): 24,944 @ $9.93 | EDGAR |
| 2026-07-28 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 41,319 @ $9.99 | EDGAR |
| 2026-07-23 | 4/A | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 6,522 @ $8.94 | EDGAR |
| 2026-07-23 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 120,582 @ $9.55 · Purchase (P): 84,124 @ $9.93 · Purchase (P): 59,880 @ $9.96 | EDGAR |
| 2026-07-22 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 98,433 @ $27.13 · Purchase (P): 32,987 @ $27.72 · Purchase (P): 21,696 @ $27.96 · Purchase (P): 6,504 @ $29.17 · Purchase (P): 37,723 @ $30 · Purchase (P): 47,250 @ $29.77 | EDGAR |
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 more | EDGAR |
| 2026-07-21 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Option exercise/expiry (X): 2,100,000 @ $0.00 · Sale (S): 213 @ $19.75 · Option exercise/expiry (X): 2,100,000 (derivative) @ $5 | EDGAR |
| 2026-07-20 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 152,472 @ $8.93 · Purchase (P): 7,882 @ $8.95 | EDGAR |
| 2026-07-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 15,102 @ $8.97 · Purchase (P): 6,552 @ $8.94 | EDGAR |
| 2026-07-01 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 70,284 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 31,000 @ $8.88 · Purchase (P): 1,876 @ $8.98 | EDGAR |
| 2026-06-26 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Sale (S): 389,216 @ $0.35 · Sale (S): 27,695 @ $0.35 | EDGAR |
| 2026-06-18 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 17,340 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Purchase (P): 6,146 @ $24.89 · Purchase (P): 61,523 @ $24.98 | EDGAR |
| 2026-06-16 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Sale (S): 159,119 @ $0.40 · Sale (S): 11,322 @ $0.40 · Sale (S): 120,216 @ $0.39 · Sale (S): 8,554 @ $0.39 · Sale (S): 139,686 @ $0.37 · Sale (S): 9,939 @ $0.37 | EDGAR |
| 2026-06-16 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 391,019 @ $8.57 · Purchase (P): 15,414 @ $8.99 · Purchase (P): 124,893 @ $8.89 | EDGAR |
| 2026-06-15 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Conversion (C): 6,556,740 · Conversion (C): 1,187,881 · Purchase (P): 19,728,353 @ $20 · Purchase (P): 1,460,397 @ $20 · Conversion (C): 642,250 (derivative) · Conversion (C): 160,562 (derivative) · +2 more | EDGAR |
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Grant/award (A): 57,162 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Nkarta, Inc. (NKTX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M. | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 20,215 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 479,039 @ $6.91 · Purchase (P): 103 @ $7 · Purchase (P): 548,580 @ $7.91 | EDGAR |
| 2026-06-11 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Sale (S): 345,235 @ $0.37 · Sale (S): 24,565 @ $0.37 · Sale (S): 42,872 @ $0.37 · Sale (S): 3,051 @ $0.37 · Sale (S): 245,066 @ $0.38 · Sale (S): 17,437 @ $0.38 | EDGAR |
| 2026-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Shah Rajeev M. | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Purchase (P): 3,802 @ $24.97 · Purchase (P): 996 @ $24.94 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-14 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Purchase (P): 6,387 @ $24.90 | EDGAR |
| 2026-05-13 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Purchase (P): 6,510,416 @ $11.52 · Purchase (P): 2,170,138 (derivative) @ $11.52 | EDGAR |
| 2026-05-12 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Sale (S): 351,514 @ $0.71 · Sale (S): 25,012 @ $0.71 · Sale (S): 81,678 @ $0.67 · Sale (S): 5,812 @ $0.67 · Sale (S): 94,432 @ $0.64 · Sale (S): 6,719 @ $0.64 | EDGAR |
| 2026-05-11 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Purchase (P): 7,921 @ $24.34 · Purchase (P): 1,985 @ $24.95 · Purchase (P): 1,483 @ $24.98 · Purchase (P): 14,149 @ $24.47 · Purchase (P): 25,720 @ $25 | EDGAR |
| 2026-05-06 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund IV, L.P., Shah Rajeev M. | Conversion (C): 3,607,846 · Conversion (C): 1,009,052 · Conversion (C): 221,188 · Purchase (P): 2,541,250 @ $18 · Purchase (P): 133,750 @ $18 · Purchase (P): 87,143 @ $24.59 · +9 more | EDGAR |
| 2026-04-29 | 4 | Adicet Bio, Inc. (ACET) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Other (J): 250,000 · Other (J): 250,000 (derivative) | EDGAR |
| 2026-04-29 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., Shah Rajeev M. | Grant/award (A): 2,106,000 (derivative) @ $9.50 | EDGAR |
| 2026-04-28 | 4 | Prelude Therapeutics Inc (PRLD) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Other (J): 1,407,000 · Other (J): 1,407,000 (derivative) | EDGAR |
| 2026-04-24 | 4 | Vor Biopharma Inc. (VOR) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Shah Rajeev M. | Sale (S): 165,150 @ $15.77 | EDGAR |
| 2026-04-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Shah Rajeev M. | Grant/award (A): 3,888,888 @ $1.80 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1384859 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →